Guanfacine to Treat Borderline Personality Disorder

Not Applicable

• Conditions: Borderline Personality Disorder

• Registration Number: NCT00358969
• Lead Sponsor: Icahn School of Medicine at Mount Sinai

Brief Summary

This study is designed to investigate whether guanfacine (Tenex) is an effective treatment for borderline personality disorder (BPD), an illness often characterized by unstable mood and impulsive aggression. Guanfacine stimulates activity in the front portion of the brain, a region associated with attention and the control of behavior. We believe that guanfacine may improve symptoms of BPD by improving attention and aiding regulation of behavior.

Detailed Description

This is an 8-week treatment study designed to test whether guanfacine is an effective treatment for borderline personality disorder (BPD). Prior to taking the study medication, subjects will have medical and psychiatric evaluations, complete self-report questionnaires, do a functional MRI scan, and complete a set of cognitive tests. While taking the study medication, participants will meet weekly with a study doctor and be administered interviews and questionnaires. At the end of the 8-week trial, participants will be asked to repeat the MRI scan and cognitive tests.

Study Timeline

• Status Verified: 2006-07
• Study Start: 2006-07
• Study First Submitted: 2006-07-31
• Study First Submitted QC: 2006-07-31
• Last Update Submitted: 2006-07-31
• Study First Posted: 2006-08-01
• Last Update Posted: 2006-08-01

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

This study includes men and women between the ages of 18 and 55 who meet criteria for borderline personality disorder with impulsive aggression.

Read More

Exclusion Criteria

Subjects must not currently be taking any psychiatric medications. Subjects must not meet criteria for current substance dependence, current major depression, bipolar disorder, or schizophrenia-spectrum disorders.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
measures of impulsive aggression
measures of affective disturbance
measures of social and occupational functioning
measures of overall clinical status

Trial Locations

Locations (1)

Mount Sinai Hospital - Mood & Personality Research Group; 🇺🇸 New York, New York, United States